null Waqqas Afif, MD, M.Sc., FRCPC
inflammatory bowel disease • Crohn's disease • ulcerative colitis • biologic medications • therapeutic drug monitoring
My research focuses on the safety and efficiency of biologic medications in the treatment of IBD. I am interested in the use of therapeutic drug monitoring to optimize the treatment of IBD patients on biologic medications.
Click on to see my current publications list
Restellini S, Khanna R, Afif W: Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Sep 15;24(10):2165-2172.
Nguyen GC, Murthy SK, Bressler B, Lam MCW, Alali A, Toumi A, Reinglas J, Rampersad A, Weizman AV, Afif W; CINERGI group. Quality of care and outcomes among hospitalized inflammatory bowel disease patients: A Multicenter Retrospective Study. Inflamm Bowel Dis. 2017 May;23(5):695-701.
Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients With Crohn's disease. Clin Gastroenterol Hepatol. 2017 Sep;15(9):1427-1434.e2.
Afif W, Sandborn WJ, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV Jr. Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013 Jun;19(7):1384-9.
Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ.Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May;105(5):1133-9.